Wende S. Hutton

Wende Hutton identifies, builds, and invests in companies that can change the practice of medicine by bringing novel drugs, technologies, and devices to market. She joined Canaan in 2004 and throughout her career she has partnered with founders to deliver more than a dozen of those innovations to patients. Her track record includes seven IPOs and six acquisitions. Wende currently sits on the boards of Antiva Biosciences, Glooko, Hyalex Orthopaedics, OncoResponse, Qlaris Bioto, and Stargazer Pharmaceuticals. Her prior investments include BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical), and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 “Fierce 15” women in biotech.